Bringing together modern molecular fingerprinting, machine learning, and cutting edge biology to evolve beyond binding-based drug development
THE CHALLENGE
97% of cancer therapies fail during clinical testing, highlighting the urgent need to improve the oncology drug development process*. While some drugs are designed to inhibit certain cancer proteins, the mechanisms-of-action for many of these drugs have been misidentified†.
Without an accurate understanding of how cancer drugs actually work, patients will receive the wrong treatments - contributing to the unacceptably-high failure rate of new therapies. Meliora is bringing the latest genomic, computational, and machine learning techniques to bear to change this paradigm. We believe that identifying the true mechanisms-of-action of chemical compounds allows more accurate, effective, and rapid drug development.
OUR PLATFORM
Meliora Therapeutics is applying modern machine learning methods to develop a first-of-its-kind atlas of drug mechanisms and their impact on cancer biology.
We leverage this target-agnostic mechanism-of-action atlas to identify potent compounds that inhibit key cancer targets, ultimately allowing us to develop better cancer therapies.
PARTNERING
We are able to provide novel mechanistic insights on existing molecules as well as identify promising starting scaffolds for de novo discovery programs.
At Meliora, we value deep interdisciplinary partnerships among our scientists and engineers. We believe that these collaborations are essential to creating our drug discovery platform and taking therapeutics to the clinic.
We have built a team of biologists, chemists, bioinformaticians, data scientists, and engineers who have a stake in our long term success and passionately believe in our mission.
JOIN OUR TEAM